NASDAQ:ATRS Antares Pharma Stock Forecast, Price & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Antares Pharma Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $2.79 +0.01 (+0.36 %) (As of 09/22/2020 12:00 AM ET) Add Compare Share Today's Range$2.75Now: $2.79▼$2.8250-Day Range$2.61MA: $2.79▼$3.1152-Week Range$1.60Now: $2.79▼$5.13Volume418,941 shsAverage Volume1.32 million shsMarket Capitalization$463.40 millionP/E Ratio69.77Dividend YieldN/ABeta1.24 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Antares Pharma, Inc. focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies worldwide. The company's injection products include OTREXUP that comprises of pre-filled methotrexate syringe and VIBEX self-injection system to enable rheumatoid arthritis (RA) and psoriasis patients to self-inject methotrexate at home; XYOSTED for the treatment of testosterone deficiency in adult males; Sumatriptan Injection USP for the acute treatment of migraine and cluster headache in adults. Its injection products also comprise Epinephrine Injection USP for treating Anaphylaxis; Makena auto injectors to reduce the risk of preterm birth in women pregnant with a single baby; ZOMAJET and Twin-Jector EZ II Needle-free Injectors to administer human growth hormone for patients with growth retardation. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; and QuickShot auto injectors. It has strategic alliances with Teva Pharmaceutical Industries, Ltd., AMAG Pharmaceuticals, Inc., and Pfizer Inc. The company was founded in 1978 and is headquartered in Ewing, New Jersey.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAntares Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $5.63, Antares Pharma has a forecasted upside of 101.6% from its current price of $2.79.Amount of Analyst CoverageAntares Pharma has only been the subject of 2 research reports in the past 90 days. Previous Next 2.8 Community Rank Outperform VotesAntares Pharma has received 392 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAntares Pharma has received 310 “underperform” votes. (Add your “underperform” vote.)Community SentimentAntares Pharma has received 55.84% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Antares Pharma and other stocks. Vote “Outperform” if you believe ATRS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ATRS will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAntares Pharma does not currently pay a dividend.Dividend GrowthAntares Pharma does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Antares Pharma insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.90% of the stock of Antares Pharma is held by insiders.Percentage Held by Institutions42.96% of the stock of Antares Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for Antares Pharma are expected to grow by 333.33% in the coming year, from $0.06 to $0.26 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Antares Pharma is 69.77, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 18.40.Price to Earnings Ratio vs. SectorThe P/E ratio of Antares Pharma is 69.77, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.71.Price to Book Value per Share RatioAntares Pharma has a P/B Ratio of 8.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.84 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryHealth Care Supplies SectorMedical Current SymbolNASDAQ:ATRS Previous Symbol CUSIP03664210 CIK1016169 Webwww.antarespharma.com Phone609-359-3020Debt Debt-to-Equity Ratio0.71 Current Ratio2.90 Quick Ratio2.41Price-To-Earnings Trailing P/E Ratio69.77 Forward P/E Ratio46.50 P/E GrowthN/A Sales & Book Value Annual Sales$123.86 million Price / Sales3.74 Cash Flow$0.00 per share Price / Cash Flow880.81 Book Value$0.33 per share Price / Book8.45Profitability EPS (Most Recent Fiscal Year)($0.01) Net Income$-2,030,000.00 Net Margins4.04% Return on Equity10.58% Return on Assets4.15%Miscellaneous Employees165 Outstanding Shares166,094,000Market Cap$463.40 million Next Earnings Date11/3/2020 (Estimated) OptionableOptionable $2.79 +0.01 (+0.36 %) (As of 09/22/2020 12:00 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive ATRS News and Ratings via Email Sign-up to receive the latest news and ratings for ATRS and its competitors with MarketBeat's FREE daily newsletter. Antares Pharma (NASDAQ:ATRS) Frequently Asked Questions How has Antares Pharma's stock been impacted by COVID-19 (Coronavirus)? Antares Pharma's stock was trading at $3.00 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ATRS stock has decreased by 7.0% and is now trading at $2.79. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Antares Pharma? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Antares Pharma in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Antares Pharma. When is Antares Pharma's next earnings date? Antares Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020. View our earnings forecast for Antares Pharma. How were Antares Pharma's earnings last quarter? Antares Pharma Inc (NASDAQ:ATRS) posted its quarterly earnings results on Thursday, August, 6th. The specialty pharmaceutical company reported $0.01 EPS for the quarter, beating the Zacks' consensus estimate of $0.00 by $0.01. The specialty pharmaceutical company had revenue of $32.38 million for the quarter, compared to the consensus estimate of $29.25 million. Antares Pharma had a net margin of 4.04% and a return on equity of 10.58%. View Antares Pharma's earnings history. What guidance has Antares Pharma issued on next quarter's earnings? Antares Pharma issued an update on its FY 2020 Pre-Market earnings guidance on Thursday, August, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $135-155 million, compared to the consensus revenue estimate of $133.28 million. What price target have analysts set for ATRS? 4 analysts have issued 12-month price targets for Antares Pharma's stock. Their forecasts range from $4.50 to $7.00. On average, they anticipate Antares Pharma's share price to reach $5.63 in the next year. This suggests a possible upside of 101.6% from the stock's current price. View analysts' price targets for Antares Pharma. Who are some of Antares Pharma's key competitors? Some companies that are related to Antares Pharma include Align Technology (ALGN), West Pharmaceutical Services (WST), Cooper Companies (COO), DENTSPLY SIRONA (XRAY), Quidel (QDEL), Haemonetics (HAE), Neogen (NEOG), ICU Medical (ICUI), STAAR Surgical (STAA), Merit Medical Systems (MMSI), Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR), Meridian Bioscience (VIVO) and Anika Therapeutics (ANIK). View all competitors. What other stocks do shareholders of Antares Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Antares Pharma investors own include Ballard Power Systems (BLDP), Advanced Micro Devices (AMD), Novavax (NVAX), NVIDIA (NVDA), Canopy Growth (CGC), Conatus Pharmaceuticals (CNAT), Prospect Capital (PSEC), Micron Technology (MU), Verizon Communications (VZ) and Enviva Partners (EVA). Who are Antares Pharma's key executives? Antares Pharma's management team includes the following people: Mr. Robert F. Apple, CEO, Pres & Director (Age 53)Mr. Fred M. Powell, Exec. VP & CFO (Age 58)Mr. Peter J. Graham, Exec. VP of HR, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 52)Dr. James Patrick Tursi, EVP, Head of R&D & Chief Medical Officer (Age 54)Mr. Keith Muckenhirn, Principal Accounting Officer, VP of Fin. & Corp. Controller (Age 56) What is Antares Pharma's stock symbol? Antares Pharma trades on the NASDAQ under the ticker symbol "ATRS." Who are Antares Pharma's major shareholders? Antares Pharma's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.86%), FMR LLC (2.78%), Sargent Investment Group LLC (2.39%), Centric Wealth Management (2.17%), Silvercrest Asset Management Group LLC (1.19%) and Oracle Investment Management Inc. (1.02%). Company insiders that own Antares Pharma stock include Jacques Gonella, Leonard S Jacob, Marvin Samson, Robert F Apple and Thomas J Garrity. View institutional ownership trends for Antares Pharma. Which institutional investors are selling Antares Pharma stock? ATRS stock was sold by a variety of institutional investors in the last quarter, including Sargent Investment Group LLC, Intrinsic Edge Capital Management LLC, Marshall Wace LLP, Marshall Wace North America L.P., UBS Group AG, Private Advisor Group LLC, Engineers Gate Manager LP, and Pinnacle Associates Ltd.. Company insiders that have sold Antares Pharma company stock in the last year include Marvin Samson, Robert F Apple, and Thomas J Garrity. View insider buying and selling activity for Antares Pharma. Which institutional investors are buying Antares Pharma stock? ATRS stock was bought by a variety of institutional investors in the last quarter, including Centric Wealth Management, FMR LLC, Asymmetry Capital Management L.P., AQR Capital Management LLC, Oracle Investment Management Inc., Assenagon Asset Management S.A., Silvercrest Asset Management Group LLC, and Goldman Sachs Group Inc.. View insider buying and selling activity for Antares Pharma. How do I buy shares of Antares Pharma? Shares of ATRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Antares Pharma's stock price today? One share of ATRS stock can currently be purchased for approximately $2.79. How big of a company is Antares Pharma? Antares Pharma has a market capitalization of $463.40 million and generates $123.86 million in revenue each year. The specialty pharmaceutical company earns $-2,030,000.00 in net income (profit) each year or ($0.01) on an earnings per share basis. Antares Pharma employs 165 workers across the globe. What is Antares Pharma's official website? The official website for Antares Pharma is www.antarespharma.com. How can I contact Antares Pharma? Antares Pharma's mailing address is 100 PRINCETON SOUTH SUITE 300, EWING NJ, 08628. The specialty pharmaceutical company can be reached via phone at 609-359-3020 or via email at [email protected] This page was last updated on 9/23/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
